<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05007301</url>
  </required_header>
  <id_info>
    <org_study_id>FSK-REG-002</org_study_id>
    <nct_id>NCT05007301</nct_id>
  </id_info>
  <brief_title>Geko™ Cross Therapy Registry - Wound</brief_title>
  <acronym>CTR-Wound</acronym>
  <official_title>Geko™ Cross Therapy Registry - Wound An Observational Study for the Post Market Clinical Follow-up of Safety and Patient Outcomes for Patients Undergoing Peroneal Nerve Stimulation by Geko™</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Firstkind Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Firstkind Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The geko™ Cross Therapy REGISTRY - Wound is a prospective, observational, anonymised data&#xD;
      collection Registry with no experimental treatment that will fulfil an unmet need for an&#xD;
      observational Registry to provide long-term clinical data to demonstrate patient benefit and&#xD;
      regulatory compliance.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The geko™ Cross Therapy REGISTRY - Wound represents a long-term project to integrate&#xD;
      prospectively and systematically collected clinical data on all geko™ W wound devices (or W&#xD;
      device variants) used in SC pathways for wound management allowing for the monitoring of&#xD;
      patient outcomes during a follow-up period of up to four follow-up visits.&#xD;
&#xD;
      The clinical database collected for the geko™ CTR - Wound will form part of the overall&#xD;
      post-market clinical follow-up strategy for the device and post market surveillance to&#xD;
      support device safety and performance. There will be up to 50 contributing centres globally.&#xD;
      Participants are asked at the time of signing up for the geko™ Cross Therapy REGISTRY - Wound&#xD;
      (at the recruitment / baseline visit) to attend as many follow up visits as possible (up to a&#xD;
      maximum of 4).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">March 2027</completion_date>
  <primary_completion_date type="Anticipated">September 2026</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>Frequency of adverse events</measure>
    <time_frame>Up to 12 months from study entry</time_frame>
    <description>Obtain frequency of adverse events (AEs) whether device related or not and compare rate to historic and published data i.e., geko™ therapy vs standard care without geko™ therapy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of serious adverse events</measure>
    <time_frame>Up to 12 months from study entry</time_frame>
    <description>Obtain frequency of serious AEs (SAEs) whether device related or not and compare rate to historic and published data i.e., geko™ therapy vs standard care without geko™ therapy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of device deficiencies</measure>
    <time_frame>Up to 12 months from study entry</time_frame>
    <description>Obtain frequency of Device Deficiencies (DD) and compare rate to historic and published data i.e., geko™ therapy vs standard care without geko™ therapy</description>
  </primary_outcome>
  <enrollment type="Anticipated">2500</enrollment>
  <condition>Wound</condition>
  <condition>Venous Leg Ulcer</condition>
  <condition>Diabetic Foot Ulcer</condition>
  <condition>Arterial Leg Ulcer</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Participants will have been identified to receive geko™ therapy as part of their standard&#xD;
        care for wound management. All participants must be at least 18 years of age and must be&#xD;
        able to provide written informed consent.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Aged ≥ 18 years&#xD;
&#xD;
          2. Intact healthy skin at the site of geko™ device application.&#xD;
&#xD;
          3. Willing and able to give written informed consent&#xD;
&#xD;
          4. Presence of an ulcerative wound to the lower leg&#xD;
&#xD;
          5. Identified to receive geko™ therapy as part of their standard care for wound&#xD;
             management.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnancy or breast feeding.&#xD;
&#xD;
          2. Use of any other neuro-modulation device.&#xD;
&#xD;
          3. Current use of TENS in the pelvic region, back or legs&#xD;
&#xD;
          4. Trauma to the lower limbs that would prevent geko™ from stimulating the common&#xD;
             peroneal nerve.&#xD;
&#xD;
          5. No response to geko™ therapy i.e., no involuntary rhythmic upward and outward movement&#xD;
             of the foot (dorsiflexion) at the maximum tolerable device setting&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Marie-Therese Targett, PhD</last_name>
    <phone>+44 (0)7340903377</phone>
    <email>marie-therese.targett@firstkindmedical.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anne-Marie Piftor</last_name>
    <phone>01494572042</phone>
    <email>anne-marie.piftor@firstkindmedical.com</email>
  </overall_contact_backup>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 5, 2021</study_first_submitted>
  <study_first_submitted_qc>August 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 16, 2021</study_first_posted>
  <last_update_submitted>August 10, 2021</last_update_submitted>
  <last_update_submitted_qc>August 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>geko</keyword>
  <keyword>wound therapy</keyword>
  <keyword>medical device</keyword>
  <keyword>registry</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetic Foot</mesh_term>
    <mesh_term>Varicose Ulcer</mesh_term>
    <mesh_term>Foot Ulcer</mesh_term>
    <mesh_term>Leg Ulcer</mesh_term>
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

